Currency In USD
| Previous Close | 23.26 |
| Open | 23.24 |
| Day High | 24.27 |
| Day Low | 23.07 |
| 52-Week High | 29.75 |
| 52-Week Low | 11.51 |
| Volume | 600,135 |
| Average Volume | 650,354 |
| Market Cap | 1.76B |
| PE | -17.43 |
| EPS | -1.37 |
| Moving Average 50 Days | 25.43 |
| Moving Average 200 Days | 22.86 |
| Change | 0.62 |
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
GlobeNewswire Inc.
Mar 02, 2026 11:01 AM GMT
Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreemen
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
GlobeNewswire Inc.
Feb 12, 2026 11:00 AM GMT
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics,
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
GlobeNewswire Inc.
Jan 12, 2026 11:00 AM GMT
Investment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating OfficerFive new